New Kisqali Combination Joins Verzenios In Englands Cancer Drugs Fund

New Kisqali Combination Joins Verzenios In England’s Cancer Drugs Fund

07:37 EDT 17 Jul 2019 | Elsevier Business Intelligence

Two of the three companies vying for an additional share of England’s CDK4/6 inhibitor market have now secured reimbur...

Original Article: New Kisqali Combination Joins Verzenios In England’s Cancer Drugs Fund

More From BioPortfolio on "New Kisqali Combination Joins Verzenios In England’s Cancer Drugs Fund"